Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

May 30, 2019

Study Completion Date

May 30, 2019

Conditions
Autism Spectrum DisorderAutistic DisorderNeurodevelopmental DisorderChildhood Developmental Disorders, Pervasive
Interventions
DRUG

Sulforaphane

The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.

DRUG

Placebo

Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.

Trial Locations (1)

27510

Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Carrboro

All Listed Sponsors
collaborator

North Carolina Translational and Clinical Sciences Institute

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT02909959 - Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder | Biotech Hunter | Biotech Hunter